Antibiotic therapy for Shigella dysentery
References
Additional references
Baer JT, Vugia DJ, Reingold AL, Aragon T, Angulo FJ, Bradford WZ. HIV infection as a risk factor for shigellosis. Emerging Infectious Diseases 1999;5(6):820‐3.
British National Formulary (BNF 53). www.bnf.org/bnf/ March 2007 (accessed 13 June 2007).
Bogaerts J, Verhaegen J, Munyabikali JP, Mukantabana B, Lemmens P, Vandeven J, et al. Antimicrobial resistance and serotypes of Shigella isolates in Kigali, Rwanda (1983 to 1993): increasing frequency of multiple resistance. Diagnostic Microbiology and Infectious Disease 1997;28(4):165‐71.
Center for Disease Control and Prevention, Division of Bacterial and Mycotic Diseases. Shigellosis. www.cdc.gov/node.do/id/0900f3ec8000755c 13 October 2005 (accessed 13 June 2007).
Datta D, Bhattacharya MK, Dutta S, Daatta A, Sarkar D, Bhandra B. Emergence of multidrug resistant Shigella dysenteriae type 1 causing sporadic outbreak in and around Kolkata, India. Journal of Health, Population, and Nutrition 2003;21(1):79‐80.
Deeks JJ, Higgins, JPT, Altman DG, editors. Analysing and presenting results. In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 8. www.cochrane.org/resources/handbook/hbook.htm (accessed 31 May 2005).
Dutta S, Rajendran K, Roy S, Chatterjee A, DuttaP, Nair GB, et al. Shifting serotypes, plasmid profile analysis and antimicrobial resistance pattern of shigellae strains isolated from Kolkata, India during 1995‐2000. Epidemiology and Infection 2002;129(2):235‐43.
Gupta A, Polyak CS, Bishop RD, Sobel J, Mintz ED. Laboratory‐confirmed shigellosis in the United States, 1989‐2002: epidemiologic trends and patterns. Clinical Infectious Diseases 2004;38(10):1372‐7.
Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/handbook/hbook.htm (accessed 1 February 2007).
Huebner J, Czerwenka W, Gruner E, von Graevenitz A. Shigellemia in AIDS patients: case report and review of the literature. Infection 1993;21(2):122‐4.
Jüni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42‐6.
Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bulletin of the World Health Organization 1999;77(8):651‐66.
Martin JM, Pitetti R, Maffei R, Tritt J, Smail K, Wald ER. Treatment of shigellosis with cefixime: two days vs. five days. Pediatric Infectious Diseases Journal 2000;19(6):522‐6.
Mates A, Eyny D, Philo S. Antimicrobial resistance trends in Shigella serogroups isolated in Israel, 1990‐1995. European Journal of Clinical Microbiology & Infectious Diseases 2000;19(2):108‐11.
Park K. Park's textbook of preventive and social medicine. 18th Edition. Jabalpur: M/S Banarsidas Bhanot Publishers, 2005.
Pazhani GP, Sarkar B, Ramamurthy T, Bhattacharya SK, Takeda Y, et al. Clonal multidrug‐resistant Shigella dysenteriae type 1 strains associated with epidemic and sporadic dysenteries in eastern India. Antimicrobial Agents Chemotherapy 2004;48(2):681‐4.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Sarkar K, Ghosh S, Nujogi SK, Bhattacharya SK. Shigella dysenteriae type 1 with reduced susceptibility to fluoroquinolones. The Lancet 2003;361(9359):785.
Shane AL, Tucker NA, Crump JA, Mintz ED, Painter JA. Sharing Shigella: risk factors for a multicommunity outbreak of shigellosis. Archives of Pediatric and Adolescent Medicine 2003;157(6):601‐3.
Shiferaw B, Shallow S, Marcus R, Segler S, Soderlund D, Hardnett FP, et al. Emerging Infections Program FoodNet Working Group. Trends in population‐based active surveillance for shigellosis and demographic variability in FoodNet sites, 1996‐1999. Clinical Infectious Diseases 2004;38 Suppl 3:175‐80.
Sinha AK, Bhattacharya SK, Sen D, Sengupta PG, Pal SC. Leukemoid reaction in Shigella dysenteriae type 1 infection. Indian Journal of Medical Research 1987;85:500‐2.
Sur D, Niyogi SK, Sur S, Datta KK, Takeda Y, Nair GB, Bhattacharya SK. Multidrug‐resistant Shigella dysenteriae type 1: forerunners of a new epidemic strain in eastern India?. Emerging Infectious Diseases 2003;9(3):404‐5.
Sur D, Ramamurthy T, Deen J, Bhattacharya SK. Shigellosis: challenges & management issues. Indian Journal of Medical Research 2004;120(5):454‐62.
Talukder KA, Khajanchi BK, Islam MA, Dutta DK, Islam Z, et al. Genetic relatedness of ciprofloxacin‐resistant Shigella dysenteriae type 1 strains isolated in south Asia. Journal of Antimicrobial Chemotherapy 2004;54(4):730‐34.
Thorpe CM, Smith WE, Hurley BP, Acheson DW. Shiga toxins induce, superinduce, and stabilize a variety of C‐X‐C chemokine mRNAs in intestinal epithelial cells, resulting in increased chemokine expression. Infections and Immunity 2001;69(10):6140‐7.
von Seidlein L, Kim DR, Ali M, Lee H, Wang X, Thiem VD, et al. A multicentre study of Shigella diarrhoea in six Asian countries: disease burden, clinical manifestations, and microbiology. PLoS Medicine 2006;3(9):e353.
World Health Organization. Dept. of Child and Adolescent Health and Development. Guidelines for the control of Shigellosis, including epidemics due to Shigella dysenteriae type 1. Geneva: World Health Organization, 2005.
World Health Organization. Shigellosis: disease burden, epidemiology and case management. Weekly Epidemiological Record 2005;80(11):94‐9.
World Health Organization. Shigella: Disease burden. www.who.int/vaccine_research/diseases/shigella/en (accessed 15 September 2006).
